前列腺特异抗原密度与良性系统性前列腺穿刺活检后前列腺癌死亡率的相关性
基于芬兰前列腺癌筛查随机研究1996—2020年数据,纳入2276例55—71岁、PSA≥4.0 ng/mL且系统性经直肠超声引导穿刺活检良性的男性。中位随访17.4年,50例死于前列腺癌。PSAD<0.15 ng/mL/cm³组15年累积前列腺癌死亡率0.5%,显著低于PSAD≥0.15 ng/mL/cm³组的2.0%(P=0.001)。PSAD联合PSA及基线变量预测前列腺癌死亡的c-statistic为0.781,优于基线变量 alone(0.737,P=0.003)及基线变量联合PSA(0.765,P=0.039)。
要点
- 良性系统性TRUS引导穿刺后前列腺癌死亡率低,中位随访17.4年2276例中50例死于前列腺癌。
- PSAD<0.15 ng/mL/cm³组15年累积前列腺癌死亡率为0.5%,PSAD≥0.15 ng/mL/cm³组为2.0%(P=0.001)。
- PSAD联合PSA及基线变量预测前列腺癌死亡的c-statistic为0.781,优于基线变量 alone(0.737,P=0.003)及基线变量联合PSA(0.765,P=0.039)。
核心结论
- 良性系统性TRUS引导穿刺活检后前列腺癌死亡率低。
- 在这些患者中,PSAD可预测前列腺癌死亡,并较其他临床变量提供额外价值。
- 基于PSAD的分层可用于指导随访策略。
研究设计与样本
- 回顾性研究,使用芬兰前列腺癌筛查随机研究(FinRSPC)1996—2020年数据。
- 纳入55—71岁、随机分至筛查组、PSA≥4.0 ng/mL且系统性TRUS引导穿刺活检良性的男性。
- 排除活检后2年内无PSA数据的10例及无前列腺体积数据的65例后,共2276例纳入分析。
主要发现
- 中位随访17.4年(四分位距13.2—20.9年),50例死于前列腺癌,1028例死于其他原因。
- PSAD<0.15 ng/mL/cm³组15年累积前列腺癌死亡率为0.5%(95%CI 0.2%—1.1%),PSAD≥0.15 ng/mL/cm³组为2.0%(95%CI 1.2%—3.1%),Grey检验P=0.001。
- PSAD联合PSA及基线变量模型的c-statistic为0.781,显著优于基线变量 alone(0.737;似然比检验P=0.003)及基线变量联合PSA(0.765;似然比检验P=0.039)。
关键数值与推荐
- PSAD截断值0.15 ng/mL/cm³用于分层。
- 基线变量包括活检时年龄、DRE结果、社会经济状况、5α-还原酶抑制剂使用、家族史及Charlson合并症指数(CCI)。
临床怎么用
- 原文结论指出,基于PSAD的分层可用于指导随访策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association between prostate-specific antigen (PSA) density (PSAD) and prostate cancer mortality after a benign result on systematic transrectal ultrasonography (TRUS)-guided prostate biopsy. PATIENTS AND METHODS: This retrospective study used data from the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC) collected between 1996 and 2020. We identified men aged 55-71 years randomised to the screening arm with PSA ≥4.0 ng/mL and a benign systematic TRUS-guided biopsy result. The cumulative prostate cancer mortality of men stratified by a PSAD cutoff of 0.15 ng/mL/cm3 was modelled with competing risk functions. The ability of PSAD, PSA, and base variables (age at biopsy, DRE result, socioeconomic status, 5α-reductase inhibitor usage, family history, and Charlson Comorbidity Index (CCI)) to predict prostate cancer death was compared using c-statistics and a likelihood ratio test. RESULTS: After excluding 10 men without PSA data within 2 years of the biopsy and 65 without prostate volume data, 2276 men were eligible for inclusion in the study. A total of 50 men died from prostate cancer and 1028 from other causes during a median (interquartile range) follow-up of 17.4 (13.2-20.9) years. The cumulative prostate cancer mortality of men with PSAD <0.15 ng/mL/cm3 was significantly lower than that of men with PSAD ≥0.15 ng/mL/cm3: 0.5% (95% confidence interval [CI] 0.2%-1.1%) vs 2.0% (95% CI 1.2%-3.1%) at 15 years (Grey's test, P = 0.001). The model consisting of PSAD, PSA and the base variables predicted prostate cancer mortality (c-statistic 0.781) significantly better than either the base variables alone (c-statistic 0.737; likelihood-ratio test, P = 0.003) or the base variables and PSA (c-statistic 0.765; likelihood-ratio test, P = 0.039). CONCLUSION: Prostate cancer mortality after a benign systematic TRUS-guided biopsy is low. In these patients, PSAD predicts prostate cancer mortality and provides additional value to other clinical variables. PSAD-based stratification can be used to guide follow-up strategy.
引用
- Pylväläinen J, Talala K, Raitanen J, et al. Association of prostate-specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy result. BJU Int. 2025. PMID: 39840544. doi:10.1111/bju.16641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。